ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	JPRN
Last refreshed on:	17 October 2023
Main ID:	JPRN-UMIN000013102
Date of registration:	01/03/2014
Prospective Registration:	Yes
Primary sponsor:	Department of Pediatrics, Tokyo Medical and Dental University
Public title:	Efficacy of Zoledronate for RAS associated ALPS like disease (RALD)
Scientific title:	Efficacy of Zoledronate for RAS associated ALPS like disease (RALD) - Zoledronate for RALD
Date of first enrolment:	2014/03/10
Target sample size:	5
Recruitment status:	Complete: follow-up complete
URL:	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015284
Study type:	Interventional
Study design:	Single arm Non-randomized
Phase:	Not selected

Countries of recruitment
Japan

Contacts

Name:	Masatoshi Takagi
Address:	Yushima1-5-45, Bunkyo-ku, Tokyo Japan
Telephone:	03-5803-5249
Email:	m.takagi.ped@tmd.ac.jp
Affiliation:	Tokyo Medical and Dental Univeristy Pediatrics

Name:	Masatoshi Takagi
Address:	Yushima1-5-45, Bunkyo-ku, Tokyo Japan
Telephone:	03-5803-5249
Email:	m.takagi.ped@tmd.ac.jp
Affiliation:	Tokyo Medical and Dental Univeristy Pediatrics

Key inclusion & exclusion criteria

Inclusion criteria:
Exclusion criteria: 1) Pregnant women and during breast feeding. 2) Uncontrollable infection 3) Serious complication such as heart, kidney and liver failure. 4) Malignancy (except for juvenile myelomonocytic leukemia) 5) Dental disease need to be treated. 6) One who is not suitable by doctor's decision.. 7) One who attended other clinical study.

Age minimum: Not applicable
Age maximum: Not applicable
Gender: Male and Female

Health Condition(s) or Problem(s) studied

RAS associated ALPS like disease (RALD)

Intervention(s)

intravenous drip infusion of Zoledronate

Primary Outcome(s)

Alleviation of autoimmunity

Secondary Outcome(s)

Reduction of immunosuppressive agents including steroid

Secondary ID(s)

Source(s) of Monetary Support

MHLW The Specified Disease Treatment Research Program

Secondary Sponsor(s)

Ethics review

Status: YES
Approval date:
Contact:

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.